- Email: [email protected]
Nuclear Androgen Receptor Content in Biopsy Specimens From Histologically Normal, Hyperplastic, and Cancerous Human Prostatic Tissue
632
ONCOLOGY AND CHEMOTHERAPY
of impotence, and 20 per cent urinary and &- per cent rectal complications. The over-all 5-year survival rate for patients with 1251 implants is 79 per cent, the survival rate decreasing with increasing T or N stage, or increasing grade of tumor. W.
W.K. 3 figures, 21 references The Stable State is not an Objective Response in Hormone-Escaped Carcinoma of Prostate AND G. D. CHISHOLM, University Department of Surgery/Urology, Western General Hospital, Edinburgh, United.Kingdom
L. L. BENYON
Brit. J. Urol., 56: 702-705 (Dec.) 1984 The authors questioned whether the stable state is an objective measure of response to treatment and whether measurement of disease changes in patients with relapse is realistic. A total of 43 patients with prostatic cancer was followed every 3 months with bone scans performed every 6 months. All patients were treated with hormones. Patients with relapse were given additional hormonal therapy, chemotherapy or palliation. Progressive disease was based on an increase of symptoms, local tumor growth and changes in the bone scan, acid and alkaline phosphatase levels, and soft· tissue metastases. With criteria established by the National Prostatic Cancer Project, only 1 of 43 patients had a partial response. There was no difference in survival in the 3 groups treated after failure of primary hormone therapy. There was no correlation between the response duration and the time to death following progression. The authors found a better survival rate if only 1 area'of progression was identified rather, than 2 or more of the 6 criteria listed. Therefore, the stable state is not an objective response to treatment but reflects the natural disease progression. J. D.S. 2 figures, 4 tables, 11 references Qualitative Analysis of Coomassie-Blue-Stained Proteins From Normal Prostate, Benign Prostatic Hypertrophy, or Adenocarcinoma of the Prostate, Separated by Two-Dimensional Protein Electrophoresis K. M. ANDERSON, J. BARANOWSKI, P. BONOMI AND S. G. ECONOMOU, Department of Medicine, Section of Medical Oncology, and Departments of Surgery and Biochemistry, Rush Medical College, Chicago, Illinois Prostate, 6: 315-323, 1985 Samples from 9 normal prostates, 10 benign hypertrophic prostates and 8 adenocarcinomas 'of the prostate obtained from the National Prostatic Cancer Project were analyzed by 2dimensional protein electrophoresis. The majority of the proteins extracted from these tissues and stained with Coomassie blue were common to all 3 types of prostate-derived samples. Based on this observation the authors hypothesize that the distribution of proteins from histologically ambiguous prostatic samples wil1'correlate moreiclosely with these protein profiles than with those associated with cancers originating from other organs. P. R. R. 6 figures, 1 table, 20 references Nuclear Andr,ogen Receptor Content in Biopsy Specimens From Histologically Normal, Hyperplastic, and Cancerous Human Prostatic Tissue
0. G. J. M. VAN AUBEL, J. BOLT-DE VRIES, M. A. BLANKENSTEIN, F. J. W. TEN KATE AND F. H. SCHRODER, Departments of Urology and Pathology, Medical Faculty, Erasmus University, Rotterdam, The Netherlands
Prostate, 6: 185-194, 1985 Androgen receptors were assayed in nuclear extracts of prostatic biopsies from 82 patients with prostatic cancer and 60 with benign prostatic hypertrophy. The exchange assay used a heparin extract, with tritium-labeled R1881 and protamine sulfate precipitation. The amount of receptor protein in benign prostatic hypertrophy and cancer specimens was equal. However, there were considerable variations in the concentration of the receptors in different patients, as well as in various portions of the prostate. Therefore, a number of biopsies from different parts of the gland may be necessary to give a mean that is representative of the entire gland. 6 figures, 1 table, 24 references Abstracter's comment. I have used immunoperoxidase to localize androgen in the prostatic tissue. The preliminary results indicate that the receptor distribution is different in various parts of the tissue. With the advent of monoclonal antibody to various receptors, location of these receptors may be possible in various parts of prostatic cancer tissue. N. J. Tissue Polypeptide Antigen (TP A) as a Prognostic Aid in Human Prostatic Carcinoma A. LEWENHAUPT, P. EKMAN, P. ENEROTH, B. NILSSON ANi;> L. NORDSTROM, Department of Urology, Huddinge
Hospital, Huddinge, Department of Urology, Research and Development Laboratory, and Department of Obstetrics and Gynecology, Institute of Cancer Epidemologics, and Department of Clinical Chemistry, Karolinska Sjukhuset, Stockholm, Sweden Prostate, 6: 285-291, 1985 Serum levels of tissue polypeptide antigen and prostatic acid phosphatase ion serum, the presence or absence of skeletal metastases, tumor grade, patient age· and erythrocyte sedimentation rate were determined in 50 patients with prostatic adenocarcinoma before onset of any therapy. Crude survival rates were estimated for 5 years after diagnosis. The prognostic value was estimated by means of the log rank test and multivariate life-table analysis. Tissue polypeptide antigen, prostatic acid phosphatase, tumor stage and erythrocyte sedimentation rate all appeared to be useful as prognostic markers. Tumor grade and patient age were not related significantly to crude survival. Tissue polypeptide antigen proved to be the most reliable prognostic marker in single test estimates as well as in a multivariate life-table analysis (p <0.01). W. W. K. 1 figure, 1 table, 30 references Antiprostate Carcinoma Monoclonal Antibody (D83.21) Cross Reacts With a Membrane Antigen Expressed on Cytomegalovirus-Transformed Human Fibroblasts
s.
A. E. CAMPBELL, M. L. BECKETT, J. J. STARLING, M. SIEG AND G. L. WRIGHT, JR., Departments of Microbiology and
Immunology, and Biochemistry, and the Immunology Program, Eastern Virginia Medical School, Norfolk, Virginia Prostate, 6: 205-215, 1985
ONCOLOGY AND CHEMOTHERAPY
of impotence, and 20 per cent urinary and &- per cent rectal complications. The over-all 5-year survival rate for patients with 1251 implants is 79 per cent, the survival rate decreasing with increasing T or N stage, or increasing grade of tumor. W.
W.K. 3 figures, 21 references The Stable State is not an Objective Response in Hormone-Escaped Carcinoma of Prostate AND G. D. CHISHOLM, University Department of Surgery/Urology, Western General Hospital, Edinburgh, United.Kingdom
L. L. BENYON
Brit. J. Urol., 56: 702-705 (Dec.) 1984 The authors questioned whether the stable state is an objective measure of response to treatment and whether measurement of disease changes in patients with relapse is realistic. A total of 43 patients with prostatic cancer was followed every 3 months with bone scans performed every 6 months. All patients were treated with hormones. Patients with relapse were given additional hormonal therapy, chemotherapy or palliation. Progressive disease was based on an increase of symptoms, local tumor growth and changes in the bone scan, acid and alkaline phosphatase levels, and soft· tissue metastases. With criteria established by the National Prostatic Cancer Project, only 1 of 43 patients had a partial response. There was no difference in survival in the 3 groups treated after failure of primary hormone therapy. There was no correlation between the response duration and the time to death following progression. The authors found a better survival rate if only 1 area'of progression was identified rather, than 2 or more of the 6 criteria listed. Therefore, the stable state is not an objective response to treatment but reflects the natural disease progression. J. D.S. 2 figures, 4 tables, 11 references Qualitative Analysis of Coomassie-Blue-Stained Proteins From Normal Prostate, Benign Prostatic Hypertrophy, or Adenocarcinoma of the Prostate, Separated by Two-Dimensional Protein Electrophoresis K. M. ANDERSON, J. BARANOWSKI, P. BONOMI AND S. G. ECONOMOU, Department of Medicine, Section of Medical Oncology, and Departments of Surgery and Biochemistry, Rush Medical College, Chicago, Illinois Prostate, 6: 315-323, 1985 Samples from 9 normal prostates, 10 benign hypertrophic prostates and 8 adenocarcinomas 'of the prostate obtained from the National Prostatic Cancer Project were analyzed by 2dimensional protein electrophoresis. The majority of the proteins extracted from these tissues and stained with Coomassie blue were common to all 3 types of prostate-derived samples. Based on this observation the authors hypothesize that the distribution of proteins from histologically ambiguous prostatic samples wil1'correlate moreiclosely with these protein profiles than with those associated with cancers originating from other organs. P. R. R. 6 figures, 1 table, 20 references Nuclear Andr,ogen Receptor Content in Biopsy Specimens From Histologically Normal, Hyperplastic, and Cancerous Human Prostatic Tissue
0. G. J. M. VAN AUBEL, J. BOLT-DE VRIES, M. A. BLANKENSTEIN, F. J. W. TEN KATE AND F. H. SCHRODER, Departments of Urology and Pathology, Medical Faculty, Erasmus University, Rotterdam, The Netherlands
Prostate, 6: 185-194, 1985 Androgen receptors were assayed in nuclear extracts of prostatic biopsies from 82 patients with prostatic cancer and 60 with benign prostatic hypertrophy. The exchange assay used a heparin extract, with tritium-labeled R1881 and protamine sulfate precipitation. The amount of receptor protein in benign prostatic hypertrophy and cancer specimens was equal. However, there were considerable variations in the concentration of the receptors in different patients, as well as in various portions of the prostate. Therefore, a number of biopsies from different parts of the gland may be necessary to give a mean that is representative of the entire gland. 6 figures, 1 table, 24 references Abstracter's comment. I have used immunoperoxidase to localize androgen in the prostatic tissue. The preliminary results indicate that the receptor distribution is different in various parts of the tissue. With the advent of monoclonal antibody to various receptors, location of these receptors may be possible in various parts of prostatic cancer tissue. N. J. Tissue Polypeptide Antigen (TP A) as a Prognostic Aid in Human Prostatic Carcinoma A. LEWENHAUPT, P. EKMAN, P. ENEROTH, B. NILSSON ANi;> L. NORDSTROM, Department of Urology, Huddinge
Hospital, Huddinge, Department of Urology, Research and Development Laboratory, and Department of Obstetrics and Gynecology, Institute of Cancer Epidemologics, and Department of Clinical Chemistry, Karolinska Sjukhuset, Stockholm, Sweden Prostate, 6: 285-291, 1985 Serum levels of tissue polypeptide antigen and prostatic acid phosphatase ion serum, the presence or absence of skeletal metastases, tumor grade, patient age· and erythrocyte sedimentation rate were determined in 50 patients with prostatic adenocarcinoma before onset of any therapy. Crude survival rates were estimated for 5 years after diagnosis. The prognostic value was estimated by means of the log rank test and multivariate life-table analysis. Tissue polypeptide antigen, prostatic acid phosphatase, tumor stage and erythrocyte sedimentation rate all appeared to be useful as prognostic markers. Tumor grade and patient age were not related significantly to crude survival. Tissue polypeptide antigen proved to be the most reliable prognostic marker in single test estimates as well as in a multivariate life-table analysis (p <0.01). W. W. K. 1 figure, 1 table, 30 references Antiprostate Carcinoma Monoclonal Antibody (D83.21) Cross Reacts With a Membrane Antigen Expressed on Cytomegalovirus-Transformed Human Fibroblasts
s.
A. E. CAMPBELL, M. L. BECKETT, J. J. STARLING, M. SIEG AND G. L. WRIGHT, JR., Departments of Microbiology and
Immunology, and Biochemistry, and the Immunology Program, Eastern Virginia Medical School, Norfolk, Virginia Prostate, 6: 205-215, 1985